CLINICAL TRIAL: THE EFFECTS OF TESTOSTERONE AND ACTONEL ON BONE DENSITY IN ANORE

临床试验：睾酮和 Actonel 对肛门骨密度的影响

• 批准号: 7731240
• 负责人: ANNE KLIBANSKI
• 金额: $ 2.2万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731240
• 关键词: Adrenal Glands; Anorexia Nervosa; Bone Density; Cells; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Eating Disorders; Fracture; Funding; Grant; Hormones; Institution; Maintenance; Muscle; Osteoblasts; Osteogenesis; Osteoporosis; Osteoporosis prevention; Ovary; Pharmaceutical Preparations; Physiological; Postmenopause; Purpose; Research; Research Personnel; Resources; Risedronate; Source; Testosterone; United States National Institutes of Health; Woman; bone; men; risedronate sodium

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Anorexia nervosa is an eating disorder that can cause thinning of the bones (a decrease in bone density). A significant decrease in bone density is called osteopenia or osteoporosis. Sometimes the loss of bone density can be severe enough to cause breaks and fractures of the bones. It is not known what causes the bones to thin in anorexia nervosa. The purpose of the study is to evaluate the effects of two different medications, physiologic testosterone replacement and risedronate, on bone density in subjects with anorexia nervosa. Testosterone is a hormone that is made by the ovaries and adrenal glands in both women and men and has been shown to be important for prevention of osteoporosis and maintenance of muscle mass in men. Testosterone has been shown to stimulate bone forming cells called osteoblasts, and to increase bone formation and bone density in post-menopausal women, but its effects on bone formation or bone density in women with anorexia nervosa are not known. Actonel is a medication that is prescribed for low bone density to postmenopausal women.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 神经性厌食症是一种饮食失调，可能导致骨骼变薄（骨密度降低）。 骨密度的显着降低称为骨质减少或骨质疏松症。 有时，骨密度的损失可能足够严重，可以引起骨骼的断裂和断裂。 尚不知道是什么导致骨骼在神经性厌食症中稀薄。 该研究的目的是评估两种不同的药物，生理睾丸激素的替代和risdronate对神经性厌食症受试者骨密度的影响。 睾丸激素是一种由男性和男性卵巢和肾上腺制成的激素，已被证明对于预防骨质疏松症和男性肌肉质量的维持至关重要。 睾丸激素已被证明可以刺激称为成骨细胞的骨形成细胞，并增加了绝经后女性的骨形成和骨密度，但尚不清楚其对神经厌食症妇女的骨形成或骨密度的影响。 Actonel是一种针对绝经后妇女的低骨密度的药物。